Floatz logo

N-Acetyl-L-Cysteine

Advanced Cancer

H. Lee Moffitt Cancer Center and Research InstitutePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

94 Active assets in the Advanced Cancer cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB
Osimertinib
NING LI
Phase 4BB
Ipilimumab
7 Hills Pharma, LLC
Phase 2BB
Irinotecan
MOMA Therapeutics
Phase 3BB

View all 50 →

Same molecule, other indications

N-Acetyl-L-Cysteine is also rated in:

idiopathic pulmonary fibrosisDormant
BBB
Indicative ·
74 / 100
View asset →
schizophreniform disorderDormant
BBB
Indicative ·
74 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →